Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) to Post Q3 2025 Earnings of ($0.32) Per Share, Wedbush Forecasts

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) – Wedbush increased their Q3 2025 EPS estimates for shares of Day One Biopharmaceuticals in a report issued on Wednesday, April 24th. Wedbush analyst R. Driscoll now anticipates that the company will earn ($0.32) per share for the quarter, up from their previous forecast of ($0.33). Wedbush currently has a “Outperform” rating and a $33.00 target price on the stock. The consensus estimate for Day One Biopharmaceuticals’ current full-year earnings is ($2.67) per share. Wedbush also issued estimates for Day One Biopharmaceuticals’ FY2025 earnings at ($1.40) EPS.

A number of other brokerages also recently issued reports on DAWN. Needham & Company LLC increased their price target on shares of Day One Biopharmaceuticals from $30.00 to $33.00 and gave the stock a “buy” rating in a report on Wednesday. Piper Sandler reissued an “overweight” rating and set a $40.00 price target on shares of Day One Biopharmaceuticals in a report on Tuesday, March 26th. The Goldman Sachs Group lowered their price target on shares of Day One Biopharmaceuticals from $50.00 to $44.00 and set a “buy” rating on the stock in a report on Tuesday, February 27th. Oppenheimer reissued a “market perform” rating on shares of Day One Biopharmaceuticals in a report on Tuesday, February 27th. Finally, JPMorgan Chase & Co. increased their price target on shares of Day One Biopharmaceuticals from $32.00 to $36.00 and gave the stock an “overweight” rating in a report on Monday, April 22nd. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $39.33.

Day One Biopharmaceuticals Price Performance

DAWN stock opened at $14.92 on Friday. The firm’s fifty day simple moving average is $15.22 and its 200-day simple moving average is $13.81. Day One Biopharmaceuticals has a 12 month low of $9.67 and a 12 month high of $17.85. The company has a market capitalization of $1.30 billion, a P/E ratio of -6.27 and a beta of -1.48.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its quarterly earnings data on Monday, February 26th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.57) by ($0.07).

Institutional Investors Weigh In On Day One Biopharmaceuticals

Hedge funds have recently modified their holdings of the business. Quest Partners LLC acquired a new stake in shares of Day One Biopharmaceuticals in the fourth quarter valued at about $29,000. China Universal Asset Management Co. Ltd. raised its position in shares of Day One Biopharmaceuticals by 130.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 2,226 shares of the company’s stock valued at $27,000 after buying an additional 1,262 shares during the last quarter. Quintet Private Bank Europe S.A. increased its position in Day One Biopharmaceuticals by 43.2% during the fourth quarter. Quintet Private Bank Europe S.A. now owns 3,313 shares of the company’s stock worth $48,000 after purchasing an additional 1,000 shares during the last quarter. Amalgamated Bank increased its position in Day One Biopharmaceuticals by 35.7% during the third quarter. Amalgamated Bank now owns 8,628 shares of the company’s stock worth $106,000 after purchasing an additional 2,268 shares during the last quarter. Finally, Exchange Traded Concepts LLC increased its position in Day One Biopharmaceuticals by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 10,072 shares of the company’s stock worth $147,000 after purchasing an additional 2,554 shares during the last quarter. 87.95% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 2,258 shares of the company’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $15.25, for a total transaction of $34,434.50. Following the completion of the transaction, the insider now directly owns 1,244,662 shares in the company, valued at $18,981,095.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 2,258 shares of the company’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $15.25, for a total transaction of $34,434.50. Following the completion of the transaction, the insider now directly owns 1,244,662 shares in the company, valued at $18,981,095.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Samuel C. Blackman sold 20,000 shares of the stock in a transaction dated Tuesday, February 27th. The shares were sold at an average price of $16.11, for a total transaction of $322,200.00. Following the completion of the sale, the insider now owns 1,224,662 shares of the company’s stock, valued at $19,729,304.82. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 55,781 shares of company stock worth $883,160. Company insiders own 8.40% of the company’s stock.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.